No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Abbott India Limited is a pharmaceutical enterprise that conducts its operations across India. The company provides an extensive portfolio of medicinal products designed for a broad spectrum of therapeutic areas, including women's health, digestive conditions, metabolic disorders, central nervous system ailments, pain management, premature labor concerns, vitamin supplementation, sleep aids, immunizations, and general consumer health items. Established in 1944, the firm was formerly known as Knoll Pharmaceuticals Limited until it officially adopted the name Abbott India Limited in July 2002. Headquartered in Mumbai, India, it operates as a subsidiary of Abbott Capital India Limited.
www.abbott.co.inNo one on the platform currently holds ABBOTINDIA.NS.
No tracked institution reports a position in ABBOTINDIA.NS as of their last filing.
No one on the platform has traded ABBOTINDIA.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 50.9% | 33.5% | 27.5% | — | — | — |
| Rev. Growth % | 8.1% | 10.0% | ||||
| Profit Margin % | 22.4% | 19.8% | 16.4% | |||
| Free Cash Flow Margin % | 24.0% | 18.7% | 15.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $75.1B | +8.5% | $814.15 | $774.22–$874.28 | — | 8 |
| 2028 | $82.2B | +9.4% | $905.61 | $828.25–$947.46 | — | 8 |
| 2029 | $90.0B | +9.5% | $1008.29 | $975.07–$1039.02 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $203.65 | $201.70 | -1.0% |
| 2026-05-11 | $186.70 | $185.80 | -0.5% |
| 2026-02-06 | $185.00 | $187.00 | +1.1% |
| 2025-11-06 | $181.55 | $195.40 | +7.6% |
| 2025-08-12 | $191.00 | $172.30 | -9.8% |
| 2025-05-15 | $158.00 | $172.71 | +9.3% |
| 2025-02-05 | $163.00 | $169.90 | +4.2% |
| 2024-11-07 | $166.00 | $168.80 | +1.7% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ABBOTINDIA.NSAbbott India Limited | $26125.00 | +2.25% | $555.1B | — |
| ALKEM.BOAlkem Laboratories Limited | $5155.00 | +1.29% | $615.4B | — |
| ALKEM.NSAlkem Laboratories Limited | $5161.00 | +1.44% | $617.1B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1664.90 | -0.63% | $957.6B | — |
| AUROPHARMA.NSAurobindo Pharma Limited |
| $1660.00 |
| -1.18% |
| $955.1B |
| — |
| GLAXO.BOGlaxoSmithKline Pharmaceuticals Limited | $2814.10 | -0.56% | $474.6B | — |
| GLAXO.NSGlaxoSmithKline Pharmaceuticals Limited | $2818.90 | -0.34% | $477.5B | — |
Source: Financial Modeling Prep · peers by sector/industry